ArticleClinical rheumatology2026
Translation, cross-cultural adaptation, validity, and reliability of the Turkish version of the Raynaud Specific Quality of Life Questionnaire (RQLQ).
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to translate and cross-culturally adapt the Raynaud-Specific Quality of Life Questionnaire (RQLQ) into Turkish, and to evaluate the psychometric properties of the Turkish version of RQLQ in patients with Raynaud's phenomenon.
methodsPatients with Raynaud's phenomenon completed the Turkish RQLQ and several validated questionnaires including the WHO-5 Well-being Index, Brief Illness Perception Questionnaire (B-IPQ), Short Form-12 (SF-12), Health Assessment Questionnaire-Disability Index (HAQ-DI), Hospital Anxiety and Depression Scale (HADS), Disabilities of the Arm, Shoulder, and Hand (DASH), and Jenkins Sleep Evaluation Scale (JSS). Construct validity was examined using correlation analyses between the Turkish RQLQ and related outcome measures. Structural validity was assessed using exploratory factor analysis (EFA). Regarding reliability, internal consistency was evaluated using Cronbach's alpha and test-retest reliability was assessed using the intraclass correlation coefficient (ICC).
resultsThe study included 88 patients with a mean age of 50.8 ± 12.2 years and RQLQ total score of 94.8 ± 28.1. The Turkish RQLQ demonstrated excellent internal consistency (Cronbach's α = 0.95) and high test-retest reliability (ICC = 0.90, 95% CI 0.81-0.95; p < 0.001). Exploratory factor analysis supported a five-factor structure consistent with the original questionnaire, explaining 69.6% of the total variance (Kaiser-Meyer-Olkin = 0.875; Bartlett's test p < 0.001). Significant correlations (p < 0.001) between the Turkish RQLQ and B-IPQ (r = - 0.646), SF-12 Physical Component Summary (r = 0.676), WHO-5 (r = 0.381), HAQ-DI (r = - 0.490), DASH (r = - 0.607), HADS-A (rho = - 0.470), and HADS-D (rho = - 0.460) supported construct validity. No substantial floor or ceiling effects were observed for the RQLQ total score (< 15%).
conclusionThe Turkish version of the RQLQ is a valid and reliable instrument for assessing disease-specific quality of life in patients with Raynaud's phenomenon. Key Points • The RQLQ was successfully translated and culturally adapted into Turkish. • The Turkish RQLQ showed excellent internal consistency and high test-retest reliability in patients with Raynaud's phenomenon. • The questionnaire demonstrated acceptable construct validity and factor analysis supported a five-factor structure consistent with the original questionnaire. • The Turkish RQLQ is a reliable and valid tool for assessing quality of life in patients with Raynaud's phenomenon.
Indexed as
Identifiers
42550356What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.